Four years after Kevin T. Conroy took the top job at a struggling biotech company, Exact Sciences Corp. said Monday it has submitted an application to federal regulators for approval to market a DNA-based, non-invasive colon cancer test. Read the full Milwaukee Journal Sentinel story here.